Literature DB >> 3185744

Antagonism of the nicotine-induced changes of the striatal dopamine metabolism in mice by mecamylamine and pempidine.

H Haikala1, L Ahtee.   

Abstract

The ability of nicotinic receptor blockers, mecamylamine and pempidine, to antagonize the changes in striatal dopamine (DA) metabolism induced by repeated nicotine administration was studied. The contents of DA and its metabolites 3-methoxytyramine (3-MT), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were measured. Mice kept at 20-22 degrees C were given nicotine, 3 mg/kg, s.c., four times, at 30 min intervals, and sacrificed 20 min after the last dose. Hexamethonium, 10 mg/kg, i.p., was administered at 30 min before the first nicotine dose in order to prevent the peripheral effects of nicotine. Mecamylamine, 0.6 or 10 mg/kg, i.p., and pempidine, 0.6 or 20 mg/kg, i.p., were given at 60 min before sacrifice. Mecamylamine and pempidine decreased clearly the striatal 3-MT content, which suggests that the nigrostriatal dopaminergic neurons are physiologically controlled by a stimulatory nicotinic mechanism. The repeatedly administered nicotine caused deep hypothermia, and increased the striatal DOPAC content but decreased the 3-MT and HVA contents. The small dose of mecamylamine, which was the only dose found to effectively antagonize the nicotine-induced hypothermia, antagonized the decrease of HVA content. The large but not the small doses of mecamylamine and pempidine antagonized the nicotine-induced increase of DOPAC content but none of the doses studied antagonized the decrease of 3-MT content. Thus it seems that nicotine decreases the 3-MT content by a mechanism distinct from the mechanism mediating the increase of the DOPAC content. The decreased 3-MT content most probably results from desensitization of nicotinic cholinergic receptors (nAChR) and following decrease of cholinergic regulation of nigrostriatal dopaminergic neurons.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3185744     DOI: 10.1007/bf00174865

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  18 in total

1.  Homovanillic acid concentration in rat brain: effect of a choline acetyltransferase inhibitor and comparison with cholinergic and dopaminergic agents.

Authors:  D R Haubrich; M E Goldberg
Journal:  Neuropharmacology       Date:  1975-03       Impact factor: 5.250

2.  The effect of nicotine on central catecholamine neurons and gonadotropin secretion. I. Studies in the male rat.

Authors:  K Fuxe; L Agnati; P Eneroth; J A Gustafsson; T Hökfelt; A Löfström; B Skett; P Skett
Journal:  Med Biol       Date:  1977-06

3.  Changes in specific activity of dopamine metabolites as evidence of a multiple compartmentation of dopamine in striatal neurons.

Authors:  A Groppetti; S Algeri; F Cattabeni; A M Di Giulio; C L Galli; F Ponzio; P F Spano
Journal:  J Neurochem       Date:  1977-01       Impact factor: 5.372

Review 4.  Acetylcholine receptor: an allosteric protein.

Authors:  J P Changeux; A Devillers-Thiéry; P Chemouilli
Journal:  Science       Date:  1984-09-21       Impact factor: 47.728

5.  Nicotinic-catecholaminergic interactions in rat brain: evidence for cholinergic nicotinic and muscarinic interactions with hypothalamic epinephrine.

Authors:  K A Roth; S L McIntire; J D Barchas
Journal:  J Pharmacol Exp Ther       Date:  1982-05       Impact factor: 4.030

6.  Nicotine-induced release of catecholamines from rat hippocampus and striatum.

Authors:  L Arqueros; D Naquira; E Zunino
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

7.  3-Methoxytyramine as an indicator of impulse-induced dopamine release in rat brain in vivo.

Authors:  W Kehr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-06       Impact factor: 3.000

8.  The nicotine-induced changes in striatal dopamine metabolism of mice depend on body temperature.

Authors:  H Haikala; T Karmalahti; L Ahtee
Journal:  Brain Res       Date:  1986-06-11       Impact factor: 3.252

9.  On the significance of endogenous 3-methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain.

Authors:  B H Westerink; S J Spaan
Journal:  J Neurochem       Date:  1982-03       Impact factor: 5.372

10.  Effect of mecamylamine on the fate of dopamine in striatal and mesolimbic areas of rat brain; interaction with morphine and haloperidol.

Authors:  L Ahtee; S Kaakkola
Journal:  Br J Pharmacol       Date:  1978-02       Impact factor: 8.739

View more
  9 in total

1.  Mecamylamine attenuates cue-induced reinstatement of nicotine-seeking behavior in rats.

Authors:  Xiu Liu; Anthony R Caggiula; Susan K Yee; Hiroko Nobuta; Alan F Sved; Robert N Pechnick; Russell E Poland
Journal:  Neuropsychopharmacology       Date:  2006-06-21       Impact factor: 7.853

2.  Nicotine effects on adults with attention-deficit/hyperactivity disorder.

Authors:  E D Levin; C K Conners; E Sparrow; S C Hinton; D Erhardt; W H Meck; J E Rose; J March
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

3.  Chronic nicotine treatment changes differentially the effects of acute nicotine on the three main dopamine metabolites in mouse striatum.

Authors:  T Leikola-Pelho; J Heinämäki; I Laakso; L Ahtee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-10       Impact factor: 3.000

4.  Mechanisms Underlying Dopaminergic Regulation of Nicotine-Induced Kinetic Tremor.

Authors:  Masaki Kato; Naofumi Kunisawa; Saki Shimizu; Higor A Iha; Yukihiro Ohno
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

5.  Nicotinic systems and cognitive function.

Authors:  E D Levin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 6.  Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

Authors:  Lauren C Smith; Olivier George
Journal:  Neuropharmacology       Date:  2020-08-03       Impact factor: 5.250

7.  Mecamylamine reverses physostigmine-induced attenuation of scopolamine-induced hyperactivity.

Authors:  M F O'Neill; A G Fernández; R W Gristwood; J M Palacios
Journal:  J Neural Transm Gen Sect       Date:  1994

8.  Nicotinic and muscarinic components of rat brain dopamine synthesis stimulation induced by physostigmine.

Authors:  J Grenhoff; T H Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-10       Impact factor: 3.000

Review 9.  More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.

Authors:  M J Moerke; L R McMahon; J L Wilkerson
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.